Treatment of Alzheimers Disease: Classical Therapeutic Approach
Samo za registrovane korisnike
2016
Autori
Bajić, Vladan P.Sudar, Emina
Spremo-Potparević, Biljana
Živković, Lada
Milićević, Zorka T.
Stanimirović, Julijana
Bogdanović, Nikola
Isenović, Esma R.
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
Ključne reči:
A beta / Alzheimers disease / cholinesterase inhibitors / hybrids / memantine / neurodegenerationIzvor:
Current Pharmaceutical Analysis, 2016, 12, 2, 82-90Izdavač:
- Bentham Science Publishers
Finansiranje / projekti:
- Hormonska regulacija ekspresije i aktivnosti azot oksid sintaze i natrijum-kalijumove pumpe u eksperimentalnim modelima insulinske rezistencije, dijabetesa i kardiovaskularnih poremećaja (RS-MESTD-Basic Research (BR or ON)-173033)
- Aberacije ćelijskog ciklusa i uticaj oksidativnog stresa na neurodegenerativne procese i malignu transformaciju ćelije (RS-MESTD-Basic Research (BR or ON)-173034)
DOI: 10.2174/1573412911666150611184740
ISSN: 1573-4129; 1875-676X
WoS: 000374885700001
Scopus: 2-s2.0-84961637983
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Bajić, Vladan P. AU - Sudar, Emina AU - Spremo-Potparević, Biljana AU - Živković, Lada AU - Milićević, Zorka T. AU - Stanimirović, Julijana AU - Bogdanović, Nikola AU - Isenović, Esma R. PY - 2016 UR - https://vinar.vin.bg.ac.rs/handle/123456789/1039 AB - Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD. PB - Bentham Science Publishers T2 - Current Pharmaceutical Analysis T1 - Treatment of Alzheimers Disease: Classical Therapeutic Approach VL - 12 IS - 2 SP - 82 EP - 90 DO - 10.2174/1573412911666150611184740 ER -
@article{ author = "Bajić, Vladan P. and Sudar, Emina and Spremo-Potparević, Biljana and Živković, Lada and Milićević, Zorka T. and Stanimirović, Julijana and Bogdanović, Nikola and Isenović, Esma R.", year = "2016", abstract = "Alzheimers disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.", publisher = "Bentham Science Publishers", journal = "Current Pharmaceutical Analysis", title = "Treatment of Alzheimers Disease: Classical Therapeutic Approach", volume = "12", number = "2", pages = "82-90", doi = "10.2174/1573412911666150611184740" }
Bajić, V. P., Sudar, E., Spremo-Potparević, B., Živković, L., Milićević, Z. T., Stanimirović, J., Bogdanović, N.,& Isenović, E. R.. (2016). Treatment of Alzheimers Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis Bentham Science Publishers., 12(2), 82-90. https://doi.org/10.2174/1573412911666150611184740
Bajić VP, Sudar E, Spremo-Potparević B, Živković L, Milićević ZT, Stanimirović J, Bogdanović N, Isenović ER. Treatment of Alzheimers Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis. 2016;12(2):82-90. doi:10.2174/1573412911666150611184740 .
Bajić, Vladan P., Sudar, Emina, Spremo-Potparević, Biljana, Živković, Lada, Milićević, Zorka T., Stanimirović, Julijana, Bogdanović, Nikola, Isenović, Esma R., "Treatment of Alzheimers Disease: Classical Therapeutic Approach" in Current Pharmaceutical Analysis, 12, no. 2 (2016):82-90, https://doi.org/10.2174/1573412911666150611184740 . .